# Evie Ring (and EvieMED)

Manufacturer: [Movano Health](/companies/movano-health)  
Category: biometric

## Summary

Movano Health's Evie Ring is a women's-health-focused smart ring (menstrual-cycle tracking, sleep, energy, heart rate, SpO2, and mood and goal trends; general-wellness, not a diagnostic) and the lifecycle-state-paused archetype of DEPLOY's biometric ring sub-cohort. The verified-vs-claimed distinction is critical: Evie Ring sales are PAUSED, not discontinued. Following Movano Health's Corvex reverse merger (closed March 19, 2026), an AI-infrastructure pivot, and a 1-for-10 reverse split, the company paused Evie Ring sales while a divestiture of its EvieMED clinical line is pending. EvieMED (the B2B/clinical variant) is an FDA 510(k)-cleared pulse oximeter and heart-rate device (December 2, 2024) for clinical trials, remote patient monitoring, and payors and pharma. DEPLOY records the consumer Evie Ring at paused availability with no current retail price. Aggregators routinely flatten this as 'Movano discontinued the Evie Ring'; the accurate state is sales-paused amid a corporate pivot, with the EvieMED divestiture pending (an intention where not yet closed). Movano Health trades as NASDAQ: MOVE (CEO John Mastrototaro).

## Top line

> Evie Ring (and EvieMED) is sales paused, no capability claims are on file, the model has no verified field deployments in the registry, and no incidents are on record.

## Readiness

- **Availability** (paused): Sales paused.
- **Price honesty** (no-price): No price points on file for Evie Ring (and EvieMED).
- **Capability honesty** (no-claims): No reviewed capability claims on file for Evie Ring (and EvieMED).
- **Real-world use** (commercial): Maturity: commercial. No verified deployments in the registry.
- **Safety record** (no-incidents): No incidents on record. No verified deployments either.

## What it claims to do

_No reviewed capability claims on file._

## Price

_No reviewed price points on file._

## Real-world use

_No verified deployments on file for Evie Ring (and EvieMED)._

## Safety record

_No incidents on record. No verified deployments either, so the absence is uninformative._

## Privacy

_No privacy practices disclosed or on file for Evie Ring (and EvieMED)._

## Specs

- **notes**: [{"label":"Verified (women's-health differentiator + the two-ring split)","value":"Movano Health (NASDAQ: MOVE; CEO John Mastrototaro) makes the women's-health-focused Evie Ring - the editorial differentiator (cycle tracking + women's-health metrics as primary positioning). KEY split: the consumer Evie Ring is GENERAL-WELLNESS (not cleared); the FDA 510(k) clearance (pulse oximeter + HR, Dec 2 2024) belongs to the separate B2B EvieMED Ring - do NOT attribute the clearance to the consumer Evie. A pivotal study showed accuracy across darker skin tones (Fitzpatrick)."},{"label":"FINANCIAL CAP-FLAG (going-concern - the real risk)","value":"Movano is financially DISTRESSED: SEC 10-Qs show going-concern substantial doubt, accumulated deficit $160.5M (Sep 30 2025), cash not sufficient beyond Q1 2026 without further capital or a merger; a strategic review / possible sale is underway; a 1-for-10 reverse split (Oct 2025) to regain NASDAQ compliance; a $1.5M bridge loan at ~111.6% effective rate secured by Movano's IP (transfers to the lender if a merger fails). maturity=commercial but AT-RISK; lifecycleState=active. RE-VERIFY before relying on (status volatile)."},{"label":"Cap-flag (source drift)","value":"A reverse-split secondary source cites a STALE Q3-2024 cash figure ($11.3M / '12 months runway') - the SEC 10-Qs SUPERSEDE it (going-concern, runway not beyond Q1 2026). Trust the 10-Q. '$40B market' framing is company TAM, not verified revenue."},{"label":"Re-verify 2026-06-03 (MATERIAL)","value":"Movano Health's strategic review resolved in a COMPLETED all-stock reverse merger with Corvex (closed Mar 19 2026; renamed Corvex, Inc. effective Mar 23 2026; same ticker NASDAQ: MOVE). The combined entity pivoted to AI cloud / GPU infrastructure (NVIDIA H200); legacy Movano shareholders retained <5%. Evie / Wellness Ring CONSUMER SALES are PAUSED and the healthcare assets (incl. the FDA-cleared EvieMED Ring) are being explored for sale/divestiture. A 1-for-10 reverse split occurred (~Oct 2025). lifecycleState active->PAUSED (sales paused, divestiture-pending; maturityStage left at commercial as the historical peak, per the active/retired split). Cap-flag: the divestiture is an INTENTION, not a closed transaction; a '$1B equity facility' and co-CEO appointments are conditional/reported-only."}]
- **specs**: TWO rings: Evie Ring (CONSUMER, women's-health-focused: menstrual-cycle tracking, sleep, energy, HR, SpO2, mood/goal trends; GENERAL-WELLNESS) + EvieMED Ring (B2B/clinical variant; FDA 510(k)-cleared pulse oximeter + HR, Dec 2 2024; for clinical trials / remote patient monitoring / payors-pharma). Company: Movano Health (NASDAQ: MOVE; CEO John Mastrototaro).
- **formFactor**: biometric (biometric-primary women's-health smart ring + AI; consumer general-wellness + B2B FDA-cleared variant)

## What's under the hood

_No brain on file for Evie Ring (and EvieMED)._

## Frequently asked questions

### Is the Evie Ring (and EvieMED) actually available for purchase?

Sales paused. Not currently available for purchase (paused, not discontinued).

_Source: [Movano EvieMED Ring FDA 510(k) clearance (pulse oximeter + HR; Dec 2 2024) - the B2B/clinical variant](https://www.prnewswire.com/news-releases/movano-health-receives-fda-clearance-for-eviemed-ring-302319677.html)._

### What does the Evie Ring (and EvieMED) cost?

Not announced.

### Where is the Evie Ring (and EvieMED) being used?

No verified field deployments on record.

### Is the Evie Ring (and EvieMED) safe?

No incidents on record, but with no verified field deployments either, the absence is uninformative.

### How does the Evie Ring (and EvieMED) handle privacy?

No privacy practices disclosed or on file for Evie Ring (and EvieMED).

### Who makes the Evie Ring (and EvieMED)?

Evie Ring (and EvieMED) is made by Movano Health, based in Pleasanton, California, USA.

_Source: [Movano EvieMED Ring FDA 510(k) clearance (pulse oximeter + HR; Dec 2 2024) - the B2B/clinical variant](https://www.prnewswire.com/news-releases/movano-health-receives-fda-clearance-for-eviemed-ring-302319677.html)._

## Manufacturer

- [Movano Health (https://www.prnewswire.com/news-releases/movano-health-receives-fda-clearance-for-eviemed-ring-302319677.html)](https://www.prnewswire.com/news-releases/movano-health-receives-fda-clearance-for-eviemed-ring-302319677.html)

## Compared to

- [Ultrahuman Ring (Air / Pro)](/consumer/models/ultrahuman-ring-air)
- [Stelo](/consumer/models/stelo)
- [Withings ScanWatch](/consumer/models/withings-scanwatch)

## Sources

1. [Movano EvieMED Ring FDA 510(k) clearance (pulse oximeter + HR; Dec 2 2024) - the B2B/clinical variant](https://www.prnewswire.com/news-releases/movano-health-receives-fda-clearance-for-eviemed-ring-302319677.html)
2. [Movano EvieMED FDA clearance; consumer Evie = women's-health metrics (cycle/sleep/mood/HR/SpO2)](https://www.mobihealthnews.com/news/movano-health-secures-fda-clearance-eviemed-ring)
3. [Movano 10-Q (FY2025): going-concern; accumulated deficit $160.5M; runway not beyond Q1 2026; strategic review](https://www.sec.gov/Archives/edgar/data/0001734750/000121390025110877/ea0261389-10q_movano.htm)
4. [Corvex to go public in all-stock merger with Movano (pivot to secure AI infrastructure)](https://www.corvex.ai/blog/press-release-corvex-to-go-public-in-all-stock-merger-withmovano-creating-a-pure-play-platform-for-secure-ai-infrastructure-and-high-performanceinference)
5. [Va. Square AI company (Corvex) goes public after merger with Movano (closed Mar 19 2026; renamed Mar 23)](https://www.arlnow.com/2026/03/25/va-square-based-ai-company-goes-public-after-merger-with-health-tech-firm/)

_Canonical: https://deploy.report/models/movano-evie-ring_